StockMarketWire.com - ValiRx said a patent covering its lead therapeutic compound VAL201 has been granted in Australia.

VAL201 has shown efficacy in prostate, breast and ovarian cancer models as well as addressing endometriosis or hormone induced abnormal cell growth in women.

At 8:54am: [LON:VAL] share price was +0.05p at 0.52p


Story provided by StockMarketWire.com